Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation
Wechsel von LMWH auf DOAKs bei krebsassoziierter venöser Thromboembolie: eine Auswertung
Thrombosis and Haemostasis · 30.01.2026
DOI: 10.1055/a-2785-8686 ↗Auf einen Blick
Bei Patient:innen mit krebsassoziierter VTE war der Wechsel von LMWH auf DOAKs mit ähnlichem Risiko für rezidivierende VTE und schwere Blutungen, aber mit geringerer Gesamtmortalität verbunden.
Fragestellung
Ist der Wechsel von LMWH auf DOAKs bei Patient:innen mit krebsassoziierter VTE wirksam und sicher?
Methode
Territoriale Kohortenstudie in Taiwan mit verknüpften Claims- und Registerdaten; 2013 bis 2021; Cox-Regression und Fine-Gray-Modelle mit inverse probability of treatment weighting.
Ergebnisse
3.885 Patient:innen; 2.373 wechselten zu DOAKs. Rezidivierende VTE: HR 0,86 (95 %-KI 0,50–1,49); schwere Blutung: HR 0,89 (95 %-KI 0,67–1,18); Gesamtmortalität: HR 0,67 (95 %-KI 0,52–0,86).
Schlussfolgerung der Autor:innen
Der Wechsel zu DOAKs ist laut den Autor:innen eine sichere und wirksame Alternative zur fortgesetzten LMWH-Therapie bei Patient:innen mit CT.
Kernaussagen
- Kein signifikanter Unterschied bei rezidivierender VTE
- Kein signifikanter Unterschied bei schwerer Blutung
- Geringeres Risiko für Gesamtmortalität unter DOAKs
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 30.01.2026. Verfasst von Wei Kang und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China. Die Arbeit nennt 50 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Although direct oral anticoagulants (DOACs) have become a primary treatment choice for cancer-associated venous thromboembolism (CT), the safety and effectiveness of switching from low-molecular-weight heparin (LMWH) to DOACs in current users remains unclear. To evaluate the safety and effectiveness of switching to DOACs in patients with CT currently receiving LMWH therapy, a territory-wide cohort study using linked claims and registry databases in Taiwan was conducted. Between 2013 and 2021, patients with CT were identified and categorized as switchers to DOACs versus persistent LMWH users. Cox regression and Fine-Gray models with inverse probability of treatment weighting were used to estimate hazard ratios (HRs) for recurrent venous thromboembolism (VTE), major bleeding, and all-cause mortality. A total of 3,885 patients with LMWH-treated CT were included, with 2,103 (54.1%) being women and a mean age of 65.6 years at CT diagnosis, of which 2,373 (59.5%) switched to DOAC therapy. Compared with the persistent use of LMWH, switching to DOACs within 6 months was associated with no significant difference in recurrent VTE (HR: 0.86 [95% CI 0.50-1.49]) and major bleeding (HR: 0.89 [95% CI 0.67-1.18]), with a significantly lower risk of all-cause mortality (HR: 0.67 [95% CI 0.52-0.86]). Switching to DOACs is a safe and effective alternative to continuous LMWH in patients with CT. This recommendation applies regardless of the duration of initial LMWH therapy, overall treatment duration, and across various vulnerable patient groups.
Autor:innen und Institutionen
- School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
- Department of Pharmacology and Pharmacy, Centre for Safe Medication Practice and Research, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
- Department of Radiation Oncology, National University Cancer Institute, National University Hospital, Singapore.
- Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
ORCID-Profile: Wei Kang, Chin-Yao Shen, Michael Chun-Yuan Cheng, Vincent K C Yan, Shing Fung Lee, Wei-Pang Chung, Caige Huang, Silvia T H Li, Yue Wei, Victor H F Lee, Stephen L Chan, Ka On Lam, Aya El Helali, Edward Chia-Cheng Lai, Esther W Chan
Zitieren
APA
Kang, W., Shen, C. Y., Cheng, M. C., Yan, V. K. C., Lee, S. F., Chung, W. P., Huang, C., Li, S. T. H., Wei, Y., Lee, V. H. F., Chan, S. L., Lam, K. O., El Helali, A., Lai, E. C., & Chan, E. W. (2026). Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation. Thrombosis and Haemostasis. https://doi.org/10.1055/a-2785-8686
Vancouver
Kang W, Shen CY, Cheng MC, Yan VKC, Lee SF, Chung WP, et al. Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation. Thrombosis and Haemostasis. 2026. doi:10.1055/a-2785-8686
BibTeX
@article{Kang2026,
author = {Kang, Wei and Shen, Chin-Yao and Cheng, Michael Chun-Yuan and Yan, Vincent K C and Lee, Shing Fung and Chung, Wei-Pang and Huang, Caige and Li, Silvia T H and Wei, Yue and Lee, Victor H F and Chan, Stephen L and Lam, Ka On and El Helali, Aya and Lai, Edward Chia-Cheng and Chan, Esther W},
title = {Switching Cancer-associated Venous Thromboembolism Treatment from Continuous LMWH to DOACs: An Evaluation},
journal = {Thrombosis and Haemostasis},
year = {2026},
doi = {10.1055/a-2785-8686}
}
EUVIMED